$HRTX
Heron Therapeutics Inc Stock $hrtx

$hrtx Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000119312516763038 Filed on November 08, 2016

Income Statement

Concept	2016 Q4	2016 Q3	2015 Q3
Revenue	$1.279M		$0.00
YoY Change
Cost Of Revenue	$35.00K
YoY Change
Gross Profit	$1.244M
YoY Change
Gross Profit Margin	97.26%
Selling, General & Admin	$18.54M	$17.49M	$8.250M
YoY Change	25.31%	112.02%	95.5%
% of Gross Profit	1490.51%
Research & Development	$29.51M	$30.24M	$14.24M
YoY Change	81.42%	112.36%	-3.33%
% of Gross Profit	2371.78%
Depreciation & Amortization	$310.0K	$300.0K	$180.0K
YoY Change	34.78%	66.67%	20.0%
% of Gross Profit	24.92%
Operating Expenses	$48.05M	$47.73M	$22.49M
YoY Change	54.69%	112.24%	18.67%
Operating Profit	-$46.80M	-$47.73M	-$22.49M
YoY Change		112.24%	18.67%
Interest Expense	$1.270M	$886.0K	$242.0K
YoY Change	414.17%	266.12%	8.04%
% of Operating Profit
Other Income/Expense, Net	-$1.160M	-$775.0K
YoY Change
Pretax Income	-$47.96M	-$48.51M	-$22.67M
YoY Change	53.52%	113.98%	18.13%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$47.96M	-$48.51M	-$22.67M
YoY Change	53.52%	113.96%	18.12%
Net Earnings / Revenue	-3750.04%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.221M	-$1.240M	-$633.8K
COMMON SHARES
Basic Shares Outstanding	39.19M		35.69M
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q4	2016 Q3	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$51.10M	$88.90M	$153.0M
YoY Change	-61.05%	-41.9%	77.49%
Cash & Equivalents	$13.41M	$45.64M	$153.0M
Short-Term Investments	$37.70M	$43.30M
Other Short-Term Assets	$3.700M	$3.100M	$2.000M
YoY Change	2.78%	55.0%	-33.33%
Inventory	$5.340M	$1.983M
Prepaid Expenses
Receivables	$1.960M
Other Receivables	$0.00
Total Short-Term Assets	$62.14M	$93.97M	$155.0M
YoY Change	-53.88%	-39.37%	73.76%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.076M	$4.702M	$2.982M
YoY Change	66.48%	57.68%	2.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$263.0K	$130.0K	$174.0K
YoY Change	484.44%	-25.29%	74.0%
Total Long-Term Assets	$5.339M	$4.832M	$3.156M
YoY Change	72.56%	53.11%	1.81%
TOTAL ASSETS
Total Short-Term Assets	$62.14M	$93.97M	$155.0M
Total Long-Term Assets	$5.339M	$4.832M	$3.156M
Total Assets	$67.48M	$98.81M	$158.2M
YoY Change	-51.05%	-37.52%	71.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.814M	$6.090M	$2.735M
YoY Change	106.48%	122.67%	82.33%
Accrued Expenses	$27.90M	$22.10M	$11.70M
YoY Change	96.48%	88.89%	40.96%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.900M	$2.700M	$2.100M
YoY Change	31.82%	28.57%	40.0%
Total Short-Term Liabilities	$38.73M	$30.93M	$16.45M
YoY Change	96.27%	88.0%	45.58%
LONG-TERM LIABILITIES
Long-Term Debt	$50.00M	$50.00M	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$50.00M	$50.00M	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$38.73M	$30.93M	$16.45M
Total Long-Term Liabilities	$50.00M	$50.00M	$0.00
Total Liabilities	$88.73M	$80.93M	$16.50M
YoY Change	349.62%	390.46%	46.02%
SHAREHOLDERS EQUITY
Retained Earnings	-$586.0M	-$538.0M	-$381.6M
YoY Change	41.94%	40.99%
Common Stock	$394.0K	$391.0K	$359.0K
YoY Change	9.14%	8.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$21.25M	$17.88M	$141.7M
YoY Change
Total Liabilities & Shareholders Equity	$67.48M	$98.81M	$158.2M
YoY Change	-51.05%	-37.52%	71.34%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2015 Q3
OPERATING ACTIVITIES
Net Income	-$47.96M	-$48.51M	-$22.67M
YoY Change	53.52%	113.96%	18.12%
Depreciation, Depletion And Amortization	$310.0K	$300.0K	$180.0K
YoY Change	34.78%	66.67%	20.0%
Cash From Operating Activities	-$38.52M	-$36.12M	-$19.89M
YoY Change	66.39%	81.6%	3.38%
INVESTING ACTIVITIES
Capital Expenditures	-$690.0K	-$540.0K	-$250.0K
YoY Change	122.58%	116.0%	212.5%
Acquisitions
YoY Change
Other Investing Activities	$5.500M	-$30.62M	$0.00
YoY Change	-109.8%
Cash From Investing Activities	$4.810M	-$31.15M	-$250.0K
YoY Change	-108.53%	12360.0%	212.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.490M	50.96M	1.600M
YoY Change	-15.34%	3085.0%	207.69%
NET CHANGE
Cash From Operating Activities	-38.52M	-36.12M	-19.89M
Cash From Investing Activities	4.810M	-31.15M	-250.0K
Cash From Financing Activities	1.490M	50.96M	1.600M
Net Change In Cash	-32.22M	-16.31M	-18.54M
YoY Change	-58.59%	-12.03%	-1.38%
FREE CASH FLOW
Cash From Operating Activities	-$38.52M	-$36.12M	-$19.89M
Capital Expenditures	-$690.0K	-$540.0K	-$250.0K
Free Cash Flow	-$37.83M	-$35.58M	-$19.64M
YoY Change	65.63%	81.16%	2.51%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2016Q3	hrtx	Accrued Clinical Liabilities AccruedClinicalLiabilities	9839000
CY2015Q4	hrtx	Accrued Clinical Liabilities AccruedClinicalLiabilities	5231000
	hrtx	Amortization Of Shortterm Investment Premium AmortizationOfShorttermInvestmentPremium	219000
	hrtx	Amortization Of Shortterm Investment Premium AmortizationOfShorttermInvestmentPremium
CY2011Q3	hrtx	Common Shares Registered For Resale In Connection With Convertible Notes CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes	3500000
CY2011Q2	hrtx	Convertible Debt Issuable In Connection With Private Placement1 ConvertibleDebtIssuableInConnectionWithPrivatePlacement1	4500000
CY2016Q3	hrtx	Convertible Notes Payable Related Parties Current ConvertibleNotesPayableRelatedPartiesCurrent	2732000
CY2015Q4	hrtx	Convertible Notes Payable Related Parties Current ConvertibleNotesPayableRelatedPartiesCurrent	2222000
CY2016Q3	hrtx	Impact On Basic And Diluted Net Loss Per Common Share In Dollars Per Share ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare	0.19
CY2015Q3	hrtx	Impact On Basic And Diluted Net Loss Per Common Share In Dollars Per Share ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare	0.08
	hrtx	Impact On Basic And Diluted Net Loss Per Common Share In Dollars Per Share ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare	0.50
	hrtx	Impact On Basic And Diluted Net Loss Per Common Share In Dollars Per Share ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare	0.27
	hrtx	Increase Decrease In Clinical Liabilities IncreaseDecreaseInClinicalLiabilities	4608000
	hrtx	Increase Decrease In Clinical Liabilities IncreaseDecreaseInClinicalLiabilities	1356000
	hrtx	Stock Issued During Period Shares Stock Options Exercised Net StockIssuedDuringPeriodSharesStockOptionsExercisedNet	652749
	hrtx	Stock Issued During Period Shares Stock Options Exercised Net StockIssuedDuringPeriodSharesStockOptionsExercisedNet	882579
CY2016Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	6090000
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3300000
CY2016Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-17000
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-40000
CY2016Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	555514000
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	530617000
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7511000
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2821000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18697000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8512000
CY2016Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	200000
CY2015Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	200000
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	510000
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	463000
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Trading Symbol TradingSymbol	hrtx
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	HERON THERAPEUTICS, INC. /DE/
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000818033
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39187594
CY2015Q3	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	0
	us-gaap	Available For Sale Securities Gross Realized Losses AvailableForSaleSecuritiesGrossRealizedLosses	0
CY2015Q4	us-gaap	Assets Assets	137845000
CY2016Q3	us-gaap	Assets Current AssetsCurrent	93974000
CY2015Q4	us-gaap	Assets Current AssetsCurrent	134751000
CY2016Q3	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	87072000
CY2015Q3	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	0
CY2016Q3	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	43279000
CY2015Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	55986000
	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	0
CY2016Q3	us-gaap	Assets Assets	98806000
	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	0
CY2016Q3	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	0
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	72675000
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	45640000
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	152989000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-29540000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	80314000
	us-gaap	Available For Sale Securities Gross Realized Losses AvailableForSaleSecuritiesGrossRealizedLosses	0
CY2016Q3	us-gaap	Available For Sale Securities Gross Realized Losses AvailableForSaleSecuritiesGrossRealizedLosses	0
CY2015Q3	us-gaap	Available For Sale Securities Gross Realized Losses AvailableForSaleSecuritiesGrossRealizedLosses	0
	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	0
CY2015Q3	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	0
	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	23000
	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	0
CY2016Q3	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	16000
CY2015Q3	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	0
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2</div><div style="display: inline; font-weight: bold;">.     B</div><div style="display: inline; font-weight: bold;">asis of Presentation</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2016 are not necessarily indicative of the results that may be expected for other quarters or the year ending December 31, 2016. The condensed consolidated balance sheet as of December 31, 2015 has been derived from the audited financial statements as of that date, but does not include all of the information and disclosures required by GAAP. For more complete financial information, these unaudited condensed consolidated financial statements and the notes thereto should be read in conjunction with the audited financial statements included in our Annual Report on Form</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> 10-K for the fiscal year ended December 31, 2015, which was filed with the Securities and Exchange Commission (the “SEC”) on February 19, 2016</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">.</div></div></div>
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	75180000
CY2016Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	88900000
CY2016Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	5500000
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	391000
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	361000
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-48525000
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22672000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-125157000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-66349000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	793000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	498000
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.24
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.63
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.34
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.07
CY2016Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8641000
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4828000
CY2016Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	55400000
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y146D
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	118000
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5333000
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4127000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15474000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11796000
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	300000
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	200000
	us-gaap	Interest Paid InterestPaid	622000
	us-gaap	Interest Paid InterestPaid
CY2016Q3	us-gaap	Inventory Net InventoryNet	1983000
CY2015Q4	us-gaap	Inventory Net InventoryNet
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2790000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	186000
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	3813000
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	658000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1983000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-271000
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	411000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-428000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	993000
CY2016Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	100000
CY2015Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	100000
CY2016Q3	us-gaap	Liabilities Liabilities	80926000
CY2015Q4	us-gaap	Liabilities Liabilities	19735000
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	98806000
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	137845000
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	30926000
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19735000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	55971000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	136232000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	10065000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-542000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-95576000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-55376000
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-48509000
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-22672000
	us-gaap	Net Income Loss NetIncomeLoss	-125180000
	us-gaap	Net Income Loss NetIncomeLoss	-66349000
CY2016Q3	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	50000000
CY2015Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	47734000
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	22491000
	us-gaap	Operating Expenses OperatingExpenses	124112000
	us-gaap	Operating Expenses OperatingExpenses	65865000
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-47734000
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-22491000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-124112000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-65865000
CY2016Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3624000
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4154000
CY2016Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	130000
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	45000
CY2016Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-16000
CY2015Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	23000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-775000
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-181000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1068000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-484000
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-55829000
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	43318000
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2446000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	783000
CY2016Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3072000
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3585000
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Reclassifications</div></div></div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Certain amounts in the 2015 financial statements have been reclassified to conform to the 2016 presentation.</div></div></div></div></div></div></div></div>
CY2011Q2	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	4300000
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	251000
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	118000
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	128199000
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	50000000
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	241000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5720000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7915000
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4702000
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3049000
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30242000
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14241000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	73620000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44920000
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-538008000
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-412828000
CY2016Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	12159000
CY2015Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4123000
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	35018000
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	9149000
	us-gaap	Share Based Compensation ShareBasedCompensation	18697000
	us-gaap	Share Based Compensation ShareBasedCompensation	8512000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	544000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	23.33
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1279000
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8435000
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8517000
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.64
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	14.42
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	8.76
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	20.42
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y343D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y313D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	653000
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	17880000
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	118110000
	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Our critical accounting policies that involve significant judgment and estimates include accrued clinical liabilities, income taxes, stock-based compensation and pre-launch inventories. Actual results could differ materially from those estimates.</div></div></div></div></div></div></div></div>
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39113000
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35773000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37470000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	32090000

Files In Submission

Name	View Source	Status
0001193125-16-763038-index-headers.html	Edgar Link	pending
0001193125-16-763038-index.html	Edgar Link	pending
0001193125-16-763038.txt	Edgar Link	pending
0001193125-16-763038-xbrl.zip	Edgar Link	pending
d256947d10q.htm	Edgar Link	pending
d256947dex101.htm	Edgar Link	pending
d256947dex102.htm	Edgar Link	pending
d256947dex103.htm	Edgar Link	pending
d256947dex311.htm	Edgar Link	pending
d256947dex312.htm	Edgar Link	pending
d256947dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g256947g67h01.jpg	Edgar Link	pending
g256947stp162new.jpg	Edgar Link	pending
g256947stp169new.jpg	Edgar Link	pending
g256947stp170.jpg	Edgar Link	pending
g256947stp183new.jpg	Edgar Link	pending
hrtx-20160930.xml	Edgar Link	completed
hrtx-20160930.xsd	Edgar Link	pending
hrtx-20160930_cal.xml	Edgar Link	unprocessable
hrtx-20160930_def.xml	Edgar Link	unprocessable
hrtx-20160930_lab.xml	Edgar Link	unprocessable
hrtx-20160930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HRTX
Heron Therapeutics Inc Stock $hrtx

2016 Q4 Form 10-Q Financial Statement

#000119312516763038 Filed on November 08, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HRTX Heron Therapeutics Inc Stock $hrtx

2016 Q4 Form 10-Q Financial Statement

#000119312516763038 Filed on November 08, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HRTX
Heron Therapeutics Inc Stock $hrtx